You are here: Industry Insights > Sandoz

News List

FDA updates on angiotensin II receptor blocker (ARB) recalls fda
November 15, 2018
FDA is alerting patients and health care professionals to Sandoz’s voluntary recall of one lot – JB8912 – of losartan potassium and hydrochlorothiazide 100mg/25mg tablets, that contain losartan, an angiotensin II receptor blocker (ARB), and hydrochlorothi
Novartis division Sandoz recalls one lot of blood pressure drug expressbpd
November 12, 2018
The drug is made by China’s Zhejiang Huahai Pharmaceutical
Sandoz Issues Recall of Losartan Potassium, Hydrochlorothiazide americanpharmaceuticalreview
November 10, 2018
Sandoz is voluntarily recalling one lot of Losartan Potassium Hydrochlorothiazide Tablets, USP 100mg/25mg to the consumer level. This product is being recalled due to the trace amount of an impurity, N-nitrosodiethylamine (NDEA) contained in the API Losar
Novartis division Sandoz recalls one lot of blood pressure drug expressbpd
November 10, 2018
The drug is made by China’s Zhejiang Huahai Pharmaceutical. Last month, the European Medicines Agency placed the firm under high supervision after a probable carcinogen was found in its blood pressure drug valsartan.
Sandoz pulls the plug on US biosimilar rituximab cphi-online
November 08, 2018
"We are disappointed to have to make this decision and stand behind the safety, efficacy and quality of our medicine, which met the stringent criteria for approval in the European Union, Switzerland, Japan, New Zealand and Australia.
Sandoz receives US FDA approval for biosimilar Hyrimoz biospectrum
November 05, 2018
Hyrimoz is third FDA-approved Sandoz biosimilar in US
Sandoz announces global resolution of biosimilar adalimumab patent disputes, securing patient access worldpharmanews
October 15, 2018
Sandoz, a Novartis division and the global leader in biosimilars, announced a global resolution of all intellectual property (IP) related litigation with AbbVie concerning the proposed Sandoz biosimilar Hyrimoz® (adalimumab)[1] for reference medicine Humi
Sandoz launches second digital health competition pharmatimes
October 11, 2018
Novartis’ generics arm Sandoz has launched the second Healthcare Access Challenge (HACk), which is looking to support digital solutions to local healthcare access challenges.
Novartis to sell Sandoz assets to Aurobindo for $900m pharmatimes
September 13, 2018
Novartis is selling parts of its generics business Sandoz to Aurobindo in a deal worth at least $900 million.
Aurobindo to acquire dermatology and oral solids businesses from Sandoz financialexpress
September 07, 2018
The acquisition is in line with Aurobindo’s strategy to grow and diversify our business in the US

Previous page 1 2 3 4 5 6 7 8 Next page